{
    "clinical_study": {
        "@rank": "88866", 
        "acronym": "AprepIt", 
        "arm_group": [
            {
                "arm_group_label": "Aprepitant", 
                "arm_group_type": "Other", 
                "description": "Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus"
            }, 
            {
                "arm_group_label": "Aprepitant after anti-itch standard therapy", 
                "arm_group_type": "Other", 
                "description": "Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week"
            }
        ], 
        "brief_summary": {
            "textblock": "Itch is a common side effect of anti-epidermal growth factor receptor antibodies and\n      tyrosine kinase inhibitors. Investigators designed a pilot single-center phase II study\n      evaluating the effects of Aprepitant, a neurokinin receptor inhibitor,  in managing\n      biological therapy-induced pruritus."
        }, 
        "brief_title": "Aprepitant in the Management of Biological Therapies-related Severe Pruritus", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "ITCH", 
        "condition_browse": {
            "mesh_term": "Pruritus"
        }, 
        "detailed_description": {
            "textblock": "Investigators enroll patients affected by solid tumors which present itch refractory to\n      standard treatment (\"refractory group\") and patients who did not receive any treatment for\n      pruritus (\"na\u00efve group\"). The intensity of itch will be evaluated with Visual Analogue Scale\n      (VAS) score. In the refractory group Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on\n      day 5) will be administered after at least 1 week of standard systemic treatment. In the\n      na\u00efve group, Aprepitant will be administered after the first onset of severe pruritus.   The\n      primary end point is to evaluate the effect of aprepitant in managing pruritus both in naive\n      and refractory group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically confirmed diagnosis of solid tumor\n\n          -  treatment with anti-EGFR antibodies or TKIs\n\n          -  first onset of severe pruritus during treatment (\u22657 on Visual Analogue Scale  (VAS)\n             score)\n\n        Exclusion Criteria:\n\n          -  oral treatment with antimycotics during 4 weeks preceding enrolment\n\n          -  topical treatment during the previous 2 weeks\n\n          -  concomitant,chronic renal or hepatic insufficiency , skin infection or dermatitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683552", 
            "org_study_id": "Aprepitant-Itch"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aprepitant", 
                    "Aprepitant after anti-itch standard therapy"
                ], 
                "description": "125 mg on day 1; 80 mg on day 3; 80 mg on day 5", 
                "intervention_name": "Aprepitant", 
                "intervention_type": "Drug", 
                "other_name": "Emend"
            }, 
            {
                "arm_group_label": "Aprepitant after anti-itch standard therapy", 
                "description": "In the refractory group (VAS score \u22657), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment  (prednisone 25 mg/die and/or fexofenadine 180 mg/die),", 
                "intervention_name": "Prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Aprepitant after anti-itch standard therapy", 
                "description": "In the refractory group (VAS score \u22657), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment  (prednisone 25 mg/die and/or fexofenadine 180 mg/die)", 
                "intervention_name": "Fexofenadine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Prednisone", 
                "Fexofenadine", 
                "Aprepitant"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ITCH", 
        "lastchanged_date": "September 11, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Roma", 
                    "country": "Italy", 
                    "zip": "00128"
                }, 
                "name": "Campus Bio-Medico of Rome University"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients", 
        "overall_official": {
            "affiliation": "Campus Bio-Medico of Rome University", 
            "last_name": "Daniele Santini, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patients is asked to grade the intensity of their itch on the VAS, with the strongest possible itch marked at the right end of the line (10) and no itch marked at the left end (0). The VAS score is registered in a diary supplied 7 days before starting the study and every week throughout the study period.\nPruritus intensity is evaluated by VAS score once before Aprepitant administration, once 7 days after the first dose of Aprepitant and once a week until the end of biological therapy or the pruritus recurrence. Response (evaluated one week after the first Aprepitant dose) is defined as > 50% reduction of pruritus intensity compared to the baseline value.", 
            "measure": "Severity of ITCH", 
            "safety_issue": "No", 
            "time_frame": "once before aprepitant  administration; 7 days after the first dose of aprepitant, and once a week until the end of biological therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683552"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Campus Bio-Medico University", 
            "investigator_full_name": "Daniele Santini", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Campus Bio-Medico University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Campus Bio-Medico University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}